Home ›
Lymphoma Trials ›
NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Trial Details
NCT ID NCT03681561
Phase PHASE1 / PHASE2
Sponsor Veronika Bachanova
Status RECRUITING
Cancer Type Lymphoma
Interventions
Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005 Indianapolis, Indiana, United States|39.76838,-86.15804 Iowa City, Iowa, United States|41.66113,-91.53017 Minneapolis, Minnesota, United States|44.97997,-93.26384 Columbus, Ohio, United States|39.96118,-82.99879
Key Eligibility Criteria
Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the infor… Age ≥ 18 years at the time of consent. ECOG Performance Status of 0, 1 or 2. Histologically confirmed diagnosis of classical Hodgkin lymphoma that is relapsed or refractory - historical biopsy at last relapse is acceptable. …
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →